scholarly journals Disease Phenotype, Activity and Clinical Course Prediction Based on C-Reactive Protein Levels at Diagnosis in Patients with Crohn’s Disease: Results from the CONNECT Study

Gut and Liver ◽  
2016 ◽  
Vol 10 (4) ◽  
pp. 595-603 ◽  
Author(s):  
Jee Hye Kwon ◽  
Jong Pil Im ◽  
Byong Duk Ye ◽  
Jae Hee Cheon ◽  
Hyun Joo Jang ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Clinical Course ◽  
Disease Phenotype ◽  
C Reactive Protein ◽  
Protein Levels ◽  
Reactive Protein

scholarly journals P578 C-reactive protein levels at first month of adalimumab treatment as predictive of nonresponse in Crohn's disease patients

2013 ◽  
Vol 7 ◽  
pp. S242
Author(s):  
E. Rodrigues-Pinto ◽  
F. Magro ◽  
F. Vilas-Boas ◽  
J. Santos-Antunes ◽  
A. Nunes ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
C Reactive Protein ◽  
Protein Levels ◽  
Reactive Protein ◽  
Adalimumab Treatment

scholarly journals Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn’s Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment

2019 ◽  
Vol 13 (1) ◽  
pp. 37-49
Author(s):  
Taketo Suzuki ◽  
Tsutomu Mizoshita ◽  
Tomoya Sugiyama ◽  
Yoshikazu Hirata ◽  
Yoshihide Kimura ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Dose Escalation ◽  
Activity Index ◽  
Disease Activity Index ◽  
Infliximab Treatment ◽  
C Reactive Protein ◽  
Protein Levels ◽  
Reactive Protein ◽  
Loss Of Response

Background/Aims: Adalimumab dose escalation is one of the most important options in refractory Crohn’s disease patients with loss of response to adalimumab. The goal of this study was to evaluate the effectiveness of adalimumab dose escalation in Crohn’s disease patients with loss of response to adalimumab, since there are few reports of adalimumab dose escalation, especially in East Asia. Methods: The clinical response to adalimumab dose escalation in Crohn’s disease patients with loss of response to adalimumab was evaluated retrospectively, using the Crohn’s disease activity index score, serum C-reactive protein levels, and endoscopic analyses. Results: Of the 203 Crohn’s disease patients treated with anti-tumor necrosis factor, 14 refractory Crohn’s disease patients with loss of response to adalimumab received adalimumab dose-escalation therapy. The C-reactive protein level was significantly reduced from the start to weeks 12 and 52 of adalimumab dose escalation in the whole group, although there were no significant reductions of Crohn’s disease activity index scores. Both Crohn’s disease activity index scores and C-reactive protein levels were significantly reduced from the start to weeks 12 and 52 of adalimumab dose escalation in patients without previous infliximab treatment, although C-reactive protein levels were positive in all cases with previous infliximab exposure at weeks 12 and 52. Endoscopic mucosal healing was achieved with adalimumab dose escalation in 2 cases without previous infliximab treatment. Conclusions: Adalimumab dose-escalation therapy is effective in refractory Crohn’s disease patients with loss of response to adalimumab, especially in cases without previous infliximab treatment.

Combined evaluation of fecal calprotectin and C-reactive protein as a therapeutic target in the management of patients with Crohn's disease

2021 ◽  
Vol 44 (2) ◽  
pp. 87-95
Author(s):  
Francisco Guilherme Cancela Penna ◽  
Rodrigo Macedo Rosa ◽  
Fernando H. Pereira ◽  
Pedro Ferrari Sales Cunha ◽  
Stella Cristina S. Sousa ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Therapeutic Target ◽  
Fecal Calprotectin ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Combined Evaluation
Sign in / Sign up

Export Citation Format

Share Document